EGFR and non-small cell lung carcinoma: First-generation EGFR-TKIs (such as gefitinib, erlotinib, and icotinib) and second-generation EGFR-TKIs (such as afatinib and dacomitinib) have established their superiority over platinum-based chemotherapy in the clinical practice for untreated advanced EGFR-mutant NSCLC patients (7–10).